Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALPS Medical Breakthroughs ETF (NY:SBIO)

48.36 UNCHANGED
Streaming Delayed Price Updated: 10:33 AM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ALPS Medical Breakthroughs ETF

News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month. 
Via Stocktwits
News headline image
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗
Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome. 
Via Stocktwits
News headline image
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome. 
Via Stocktwits
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗
Via Stocktwits
News headline image
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder ↗
The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder. 
Via Stocktwits
News headline image
Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗
The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder. 
Via Stocktwits
News headline image
Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗
DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder. 
Via Stocktwits
News headline image
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗
The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it. 
Via Stocktwits
News headline image
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens ↗
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed ↗
The company expects to announce a new CFO “in the coming months.” 
Via Stocktwits
Topics Earnings
News headline image
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? ↗
Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena. 
Via Stocktwits
News headline image
5 Small-Cap ETFs At The Forefront Of The Latest Rally ↗
We have highlighted ETFs from the space that are at the forefront of the market rally over the past week. 
Via Talk Markets
Topics ETFs
News headline image
The Short-Term Trend Is Uncertain, But Stocks Are Showing Momentum ↗
I'm still not certain about the short-term trend in the markets, but I can see that most stocks are now showing bullish, upward momentum. Although the PMO index has been choppy over the last four... 
Via Talk Markets
News headline image
5 Market-Beating Sector ETFs Of December ↗
Wall Street sizzled in December. The rally came on the back of optimism that the Fed would cut its interest rates sooner than expected and that the U.S. economy would avoid a recession. Here is a look... 
Via Talk Markets
Topics ETFs Economy
News headline image
5 Top-Performing Sector ETFs Of Q2 ↗
There are winners from many corners of the space. Here is one ETF each from the five best sectors of the second quarter. 
Via Talk Markets
News headline image
Biotech ETFs Pop On M&A Resurgence ↗
The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A). 
Via Talk Markets
News headline image
5 Sector ETFs That Beat the Market in Apri ↗
While most of the segments rallied last month, these five ETFs from different corners of the market led the way higher. 
Via Talk Markets
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
5 ETFs Riding High On The Biotech Comeback ↗
The high-growth biotech segment has borne the maximum brunt of the broader market sell-off. 
Via Talk Markets
News headline image
7 Best Biotech Stocks to Buy in July 2022 ↗
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
News headline image
Biotech ETFs That Outperformed Last Week ↗
Though the broad U.S. market saw a tumultuous ride last week with most of the sectors in red, biotechnology was the biggest gainer. 
Via Talk Markets
News headline image
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index ↗
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: 
Via Benzinga
News headline image
Top-Performing Biotech ETFs of Last Week ↗
Investors may want to tap the bullishness in the biotech sector with the best biotech ETFs of last week. 
Via Talk Markets
News headline image
5 Small-Cap Sector ETFs Leading the Russell 2000 Rally ↗
Here are five ETFs from different sectors that have easily crushed the Russell 2000 Index over the past month and are likely to continue their strong performance for the rest of the year. 
Via Talk Markets
News headline image
Medical Miracles Inside Biotech ETFs ↗
The events of the past year focused a lot of attention on game changing developments made possible by the global biotech industry. Of the major names Moderna is the one where the original research and... 
Via Talk Markets
Topics Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.